Celltrion, Inc. Stock Korea S.E.
Equities
068270
KR7068270008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- KRW | - |
Apr. 17 | Celltrion, Inc. announces an Equity Buyback for 436,047 shares. | CI |
Apr. 17 | Celltrion, Inc. authorizes a Buyback Plan. | CI |
Sales 2024 * | 3,428B 2.49B | Sales 2025 * | 4,172B 3.03B | Capitalization | 37,040B 26.89B |
---|---|---|---|---|---|
Net income 2024 * | 505B 367M | Net income 2025 * | 1,099B 798M | EV / Sales 2024 * | 11 x |
Net Debt 2024 * | 656B 476M | Net Debt 2025 * | 297B 215M | EV / Sales 2025 * | 8.95 x |
P/E ratio 2024 * |
71.6
x | P/E ratio 2025 * |
33.3
x | Employees | - |
Yield 2024 * |
0.23% | Yield 2025 * |
0.24% | Free-Float | 63.67% |
Managers | Title | Age | Since |
---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 07-04-23 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 49 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Soon-Woo Lee
BRD | Director/Board Member | 73 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jong-Seok Lee
BRD | Director/Board Member | 72 | 14-12-07 |
1st Jan change | Capi. | |
---|---|---|
-0.02% | 42.11B | |
+48.54% | 40.08B | |
+5.04% | 40B | |
+5.25% | 24.58B | |
-23.83% | 18.44B | |
-1.62% | 11.94B | |
+22.75% | 11.66B | |
+6.44% | 11.01B | |
-18.61% | 9.87B |
- Stock Market
- Equities
- A068270 Stock
- 068270 Stock